Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 316

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 19
Chunk 316
---
, Sanofi still retains a license option for a third preclinical molecule.

Refer to Notes 2. p and 13 for accounting description.

License agreement with Takeda signed in 2023

On April 3, 2023, the Company announced that it has entered into an exclusive license agreement with Takeda under which Innate grants Takeda exclusive worldwide rights to research and develop antibody drug conjugates (ADC) using a panel of selected Innate antibodies against an undisclosed target, with a primary focus in Celiac disease. Takeda would be responsible for the future development, manufacture and commercialization of any potential products developed using the licensed antibodies. As such, the Company considered that the license granted was a right to use the intellectual property, which was granted fully and perpetually to Takeda. On July 25, 2024, the Company received a letter from Takeda terminating the exclusive license agreement signed on March 31, 2023. Termination was effective at the end of a 90

Refer to Notes 2. p and 13 for accounting description.

1.2. Key events

a)Key events for the year ended December 31, 2024

On March 6, 2024, the Company announced the first patient was dosed in its Phase 1/2, investigating the safety and tolerability of IPH6501, a first-in-class CD20-targeting tetraspecific natural killer cell engager, from ANKET® platform, in patients with Relapsed and/or Refractory CD20-expressing B-cell Non-Hodgkin’s Lymphoma.

On April 15, 2024, the Company announced that the first patient was dosed in the Phase 2 dose expansion part of the Sanofi-sponsored clinical trial of SAR443579 / IPH6101, evaluating SAR443579 as a monotherapy for the treatment of blood cancers. Under the terms of the 2016 research collaboration with Sanofi, the progression to the dose expansion part of the trial has triggered a milestone payment from

F-18

Sanofi to Innate of € 4

On June 10, 2024, the Executive Board carried out a capital increase of € 5,342 106,844 68,744 68,744 0.05 38,100 0.05 2.45 91,440

On July 25, 2024, the Company received from Taked